This symposium will discuss a genetically-inspired classification of MDS aimed at improving clinical decision making. The clinical relevance of genetic predisposition to myeloid malignancies will also be analyzed. Allogeneic transplantation is the only potentially curative treatment for MDS but is associated with substantial morbidity and mortality; evidence that transplantation can improve survival rates for older patients with higher-risk MDS will be presented. Finally, you will hear case-based presentations focused on MDS patients with cardiovascular comorbidity, those with TP53 mutation, and anemic patients with clonal cytopenia of undetermined significance (CCUS).
This activity is designed for an audience of physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
Upon completion of the educational activity, participants should be able to:
Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Head Hematology Site Group
Co-Director of MDS Research Program
Odette Cancer Center
Toronto, Ontario, Canada
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, USA
Memorial Sloan Kettering Cancer Center
New York City, NY USA
Associate Professor of Hematology
Department of Molecular Medicine, University of Pavia &
Unit of Precision Hematology, IRCCS S. Matteo Hospital Foundation
Director, Department of Medicine
Tel-Aviv Sourasky Medical Center
Professor of Haemato-Oncology
Director of BMS-Celgene & King’s College London Research Programme
King’s College London & King’s College Hospital
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Malignant Hematology Department
Tampa, FL, USA
Rochester, MN, USA
Co-Chairs: Mario Cazzola, MD (Pavia, Italy), Rena Buckstein, MD (Toronto, Canada)
|7:00 – 7:10 am||Welcome & Program Overview and Objectives
Stephen Nimer, MD (MDSF Chairman) and Mario Cazzola, MD
|7:10 – 7:35 am||While the WHO Classification of MDS has Helped our Patients, We Should Now Move to a Genetically-Inspired Classification
Elsa Bernard, PhD
New York City, New York, USA
|7:35 – 8:00 am||When and How Genetic Predisposition to MDS Should be Taken into Account in Clinical Decision Making
Luca Malcovati, MD
|8:00 – 8:25 am||Can Transplantation Improve Survival Rates For Older Patients with Higher-Risk MDS
Ghulam Mufti, DM, FRCP, FRCPath
London, United Kingdom
|8:25 – 8:55 am||An Elderly Patient With MDS, Thrombocytopenia, and a Cardiovascular Comorbidity that Requires Anticoagulation or Antiplatelet Therapy
Moshe Mittelman, MD
Tel Aviv, Israel
|8:55 – 9:25 am||A Patient with a Myeloid Neoplasm and a TP53 Mutation
David Sallman, MD
Miami, Florida, USA
|9:25 – 9:55 am||An Anemic Patient with CCUS
Zhuoer Xie, MD
Rochester, Minnesota, USA
|9:55 – 10:00 am||Closing Remarks
Mario Cazzola, MD and Rena Buckstein, MD
CRITERIA FOR SUCCESS
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form at https://www.mds-foundation.org/learning-center/2021-ash-registration-form/.
You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at firstname.lastname@example.org.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3 contact hours.
3 ANCC contact hours
AAPA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This activity is supported by an educational grant from Geron Corporation, Gilead Sciences, Inc., and Taiho Oncology, Inc. Any additional support received will be disclosed prior to start of activity.
AMERICANS WITH DISABILITIES ACT
AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.
*Activity and faculty subject to change
**Please note that CME credits will only be available to participants that attend the live symposium.